Enbridge Announces Conversion Results for Series 9 Preferred Shares
CALGARY, AB, Nov. 18, 2024 /PRNewswire/ – Enbridge Inc. (TSX: ENB) (NYSE: ENB) (Enbridge) announced today that none of its outstanding Cumulative Redeemable Preference Shares, Series 9 (Series 9 Shares) will be converted into Cumulative Redeemable Preference Shares, Series 10 (Series 10 Shares
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha–particle emitting radioisotope, actinium–225, for potential cancer treatments The two sides aim to submit an Investi
Medeze Group Honoured with Industry Champions of the Year Award for Advancements in Longevity Science and Regenerative Healthcare
BANGKOK, Nov. 19, 2024 /PRNewswire/ — Medeze Group Public Company Limited (Medeze Group), Thailand’s foremost hematopoietic (HSC), mesenchymal stem cell (MSC) bank and leader in regenerative healthcare, has received the esteemed Industry Champions of the Year Award at the 2024 Asia Corpo
" title="OTOY, in association with William Shatner and the Nimoy Estate, releases ‘765874 Unification,’ commemorating 30th anniversary of “Star Trek: Generations” with an immersive media experience for The Archive
On the 30th anniversary of “Star Trek: Generations”, The Archive and William Shatner revisit Captain Kirk’s final appearance on screen in a new 8-minute video produced for The Archive app on Apple Vision Pro: “765874: Unification”, launched in tandem with new interactiv
Media Advisory – Deputy Prime Minister’s itinerary for Tuesday, November 19, 2024
OTTAWA, ON, Nov. 18, 2024 /CNW/ – Note: All times local. Ottawa, Ontario Private meetings. 10:00 a.m. The Deputy Prime Minister will chair a meeting of the Cabinet Committee on Canada-U.S. Relations. Closed to media. 1:00 p.m. The Deputy Prime Minister will provide an update
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy
SHANGHAI, Nov. 19, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON
Machine Translation Market to Grow by USD 1.23 Billion (2024-2028), Driven by Content Localization Demand, with AI Redefining Market Landscape – Technavio
NEW YORK, Nov. 18, 2024 /PRNewswire/ — Report with market evolution powered by AI – The global machine translation market size is estimated to grow by USD 1.23 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 15.89% during the forecast p
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Lilium N.V. – LILM
NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Lilium N.V. (“Lilium” or the “Company”) (NASDAQ: LILM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Evolv Technologies Holdings, Inc. – EVLV
NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Evolv Technologies Holdings, Inc. (“Evolv” or the “Company”) (NASDAQ: EVLV). Such investors are advised to contact Danielle Peyton at [email protected]
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against WM Technology, Inc. – MAPS
NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against WM Technology, Inc. (“WM” or the “Company”) (NASDAQ: MAPS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,
